Jacqueline Anne Turner

Ms. Jacqueline Anne Turner


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JTJacqueline Anne Turner
Jacqueline Anne Turner
MFMalia A. Fredrickson
Malia A. Fredrickson
MDMarc D’antonio
Marc D’antonio
EKElizabeth Katsnelson
Elizabeth Katsnelson
MMMorgan MacBeth
Morgan MacBeth
RTRaul M. Torres
Raul M. Torres
Lysophosphatidic acid (LPA) is a bioactive lipid which increases in concentration locally and systemically across different cancer types. Yet, the exact mechanism(s) of how LPA affects CD8 T cell immunosurveillance during tumor progression remain unknown. We show LPA receptor (LPAR) signaling by CD8 T cells promotes tolerogenic states via metabolic reprogramming and potentiating exhaustive-like differentiation to modulate anti-tumor immunity. We found LPA levels predict response to immunotherapy and Lpar5 signaling promotes cellular states associated with exhausted phenotypes on CD8 T cells. Importantly, we show that Lpar5 regulates CD8 T cell respiration, proton leak, and reactive oxygen species. Together, our findings reveal that LPA serves as a lipid-regulated immune checkpoint by modulating metabolic efficiency through LPAR5 signaling on CD8 T cells. Our study offers key insights into the mechanisms governing adaptive anti-tumor immunity and demonstrates LPA could be exploited as a T cell directed therapy to improve dysfunctional anti-tumor immunity.

23 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JTJacqueline Anne Turner
Jacqueline Anne Turner
EPEmily Paton
Emily Paton
RGRobert Van Gulick
Robert Van Gulick
DSDavide Stefanoni
Davide Stefanoni
FCFrancesca Isabelle Cendali
Francesca Isabelle Cendali
Isabel SchlaepferIsabel Schlaepfer
Isabel Schlaepfer
There is increasing evidence that oxidative metabolism and fatty acids play an important role in BRAF-driven tumorigenesis, yet the effect of BRAF mutation and expression on metabolism is poorly understood. We examined how BRAF mutation and expression modulates metabolite abundance. Using the non-transformed NIH3T3 cell line, we generated cells that stably overexpressed BRAF V600E or BRAF WT. We found that cells expressing BRAF V600E were enriched with immunomodulatory lipids. Further, we found a unique transcriptional signature that was exclusive to BRAF V600E expression. We also report that BRAF V600E mutation promoted accumulation of long chain polyunsaturated fatty acids (PUFAs) and rewired metabolic flux for non-Warburg behavior. This cancer promoting mutation further induced the formation of tunneling nanotube (TNT)-like protrusions in NIH3T3 cells that preferentially accumulated lipid droplets. In the plasma of melanoma patients harboring the BRAF V600E mutation, levels of lysophosphatidic acid, sphingomyelin, and long chain fatty acids were significantly increased in the cohort of patients that did not respond to BRAF inhibitor therapy. Our findings show BRAF V600 status plays an important role in regulating immunomodulatory lipid profiles and lipid trafficking, which may inform future therapy across cancers.

23 September 2022 in Research Square
Verified
Preprint
Open access
PDF file
JTJacqueline Anne Turner
Jacqueline Anne Turner
MFMalia Fredrickson
Malia Fredrickson
MDMarc D'Antonio
Marc D'Antonio
MMMorgan MacBeth
Morgan MacBeth
RGRobert Van Gulick
Robert Van Gulick
RTRaul Torres
Raul Torres
Lysophosphatidic acid (LPA) is a bioactive lipid which increases in concentration locally and systemically across different cancer types. Yet, the exact mechanism(s) of how LPA affects CD8 T cell immunosurveillance during tumor progression remain unknown. We show LPA receptor (LPAR) signaling by CD8 T cells promotes tolerogenic states via metabolic reprogramming and potentiating exhaustive differentiation to modulate anti-tumor immunity. We found LPA levels predict response to immunotherapy and Lpar5 signaling drives exhausted phenotypes on CD8 T cells. Importantly, we identify a novel function of Lpar5 to regulate CD8 T cell respiration, proton leak, and reactive oxygen species. Together, our findings reveal that LPA serves as a lipid-regulated immune checkpoint by modulating metabolic efficiency through LPAR5 signaling on CD8 T cells. Our study offers key insights into the mechanisms governing adaptive anti-tumor immunity and demonstrates LPA could be exploited as a novel T cell directed therapy to improve dysfunctional anti-tumor immunity.

6 March 2024 in Case Reports in Immunology
Verified
Journal Article
Open access
PDF file
JTJacqueline Anne Turner
Jacqueline Anne Turner
AHAli Hakimi
Ali Hakimi
HLHannah Lee
Hannah Lee
JSJeffrey T. Schowinsky
Jeffrey T. Schowinsky
JSJeffrey M. Sippel
Jeffrey M. Sippel
WRWilliam Robinson
William Robinson
The Castleman triad has been described in a select few patients presenting with a retroperitoneal mass, mucocutaneous pemphigus vulgaris, and bronchiolitis obliterans. Here, we describe the Castleman triad in a 19-year-old male with unicentric hyaline vascular type Castleman disease (HV-CD). This patient presented with an array of positive antibodies, including anti-cyclic citrullinated peptide, anti-double-stranded DNA, and Sjogren’s IgG. Interestingly, the patient’s rheumatologic symptoms resolved after tumor resection, while his antibody profile remained relatively unchanged. HV-CD, with a triad presentation, was thought to be from a paraneoplastic syndrome secondary to an underlying lymphoproliferative disorder. The findings presented here identify multiple autoantibodies potentially contributing to this patient’s presentation with HV-CD.

6 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAlexander C. Goodman
Alexander C. Goodman
KMKylie M. Michel
Kylie M. Michel
MMMorgan MacBeth
Morgan MacBeth
JTJacqueline Anne Turner
Jacqueline Anne Turner
RTRichard Tobin
Richard Tobin
KCKasey L. Couts
Kasey L. Couts
Objectives: This study investigates the relationship between serum oxylipin profiles and response to immune checkpoint inhibitor therapy in melanoma subtypes to identify potential metabolic biomarkers for treatment response. Methods: In a retrospective cohort study, serum samples from 43 stage III and stage IV melanoma patients treated at the University of Colorado Hospital from 2010 to 2023 were analyzed via ultra-high-pressure liquid chromatography-mass spectrometry. Melanoma patients were treated anti-PD-1 monotherapy or combination immune checkpoint inhibitor therapy and response was assessed using RECIST 1.1 criteria. Results: Using mass spectroscopy, we determined global oxylipin metabolite profiles are largely uniform pre-and post-treatment across melanoma subtypes including cutaneous, acral, mucosal, and uveal melanoma. Across subtypes, 33 oxylipin metabolites were analyzed, with limited variation observed overall. Prostaglandin J 2 was more abundant in rare melanoma subtypes including acral, mucosal, and uveal melanoma compared to cutaneous melanoma. Conclusions: Despite limited variation of serum oxylipin molecular species by subtype and response status, we observed significant differences in Prostaglandin J 2 which could serve as a potential biomarker for immune checkpoint inhibitor therapy response in melanoma. However, further investigation is warranted to explore the role of oxylipins in immune response modulation.

10 August 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
MMMorgan MacBeth
Morgan MacBeth
SBStacey M. Bagby
Stacey M. Bagby
JBJessica Borgers
Jessica Borgers
JTJacqueline Anne Turner
Jacqueline Anne Turner
KAKelsey Anderson
Kelsey Anderson
KCKasey L. Couts
Kasey L. Couts
Rare melanoma subtypes, including acral, mucosal, and uveal melanomas, exhibit limited responses to immune checkpoint inhibitors (ICI), yet the molecular mechanisms of immune resistance remain poorly defined. This study aimed to characterize transcriptional programs associated with immune evasion across melanoma subtypes and identify strategies to restore immune gene expression in rare melanomas. We performed transcriptomic profiling of xenografts derived from patients with melanoma and publicly available tumor datasets to compare intratumoral gene expression across cutaneous and rare melanoma subtypes. Cross-subtype analysis revealed convergent downregulation of innate immune pathogen sensing (IIPS) and type I interferon signaling pathways in rare melanomas compared with cutaneous tumors. Lower IIPS expression correlated with nonresponse to PD-1 blockade, which was associated with reduced CD8+ and memory CD4+ T-cell infiltration and enrichment of M2 macrophages inferred by CIBERSORT. Immunomodulatory compounds were screened in vitro to identify IIPS-inducing drugs, and decitabine was further evaluated in mucosal and uveal melanoma xenograft models. Decitabine treatment robustly induced IIPS and antigen presentation genes in rare melanoma cell lines and xenografts, with RNA sequencing confirming IIPS reexpression as the dominant transcriptional consequence. Silencing of IIPS genes represents a recurrent immune evasion mechanism in rare melanomas. Decitabine reverses this silencing, restoring innate and adaptive immune gene expression, and may serve as a therapeutic priming strategy to enhance ICI responsiveness in patients with rare melanoma subtypes.